TADALAFIL IN PATIENTS WITH BENIGN PROSTATIC HYPERPLASIA DURING CONSERVATIVE COMBINED THERAPY


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The article presents the results of treatment of 155 patients with BPH aged 48-65 years, who received conservative treatment for this disease. The patients were divided into three groups. Group 1 consisted of patients with BPH and erectile dysfunction (ED), who underwent conservative treatment (5a-reductase inhibitors in combination with a1-adrenoblocker) and phosphodiesterase inhibitor (tadalafil 20 mg) on demand. Group 2 consisted of patients with prostatic adenoma and ED, who received only conservative therapy. Group 3 consisted of BPH patients without ED, who received only conservative therapy. The effectiveness of treatment was assessed using patient self-assessment questionnaire. I-PSS score was used for the assessment of symptoms of the disease, for assessment of sexual function - AMS questionnaire for the age-related symptoms in men (specific section), short BSFI questionnaire, and International Index of Erectile Function (IIEF-5). Questionnaire survey was performed before treatment and 3, 6 and 9 months after therapy. Analysis of the results showed that there were significant impairments of sexual function in BPH. The use of phosphodiesterase inhibitor against the background of conservative therapy improves erectile function, and reduces the intensity of urination disorders.

Full Text

Restricted Access

References

  1. Roehrborn C.G., Briganti A., Capitanio U. et al. Benign prostatic hyperplasia and Its Aetiologies. Eur. Urol. 2009; 8(Suppl.):865-871.
  2. Лоран О.Б., Лукьянов И.В. Практическая урология: что нового в лечении ДГПЖ - взгляд зксперта. РМЖ. 2008;29:1988.
  3. Kirby R. Improving lower urinary tract symptoms in BPH. The Practitioner 2011;255(1739):15—19.
  4. Roehrborn C.G., Siami P., Barkin J. et al. The Effects of Combination Therapy with Dutasteride and Tamsulosin on Clinical Outcomes in Men with Symptomatic Benign Prostatic Hyperplasia: 4-Year Results from the CombAT Study. Eur. Urol. 2010;57:123-131.
  5. Donnell R.F. Benign prostate hyperplasia: a review of the year's progress from bench to clinic. Curr. Opin. Urol. 2011;21(1):22—26.
  6. Болдуин Д. Сексуальное здоровье мужчини. М., 1995. С. 24-37.
  7. Зль'Мазбух А.М., Пушкарь Д.Ю. Сексуальная дисфункция у больниїх с расстройствами мочеиспускания при доброкачественной гиперплазии предстательной желези // Андрология и генитальная хирургия. 2005;2:12-19.
  8. Aytaс I.A., Mckinlay J.B., Krane R.J. The likely worldwide increase in erectile dysfunction between 1995 and 2025 and some possible policy consequences. BJU Int. 1999;84(l):50-56.
  9. Moncada I. LUTS: A risk factor for sexual dysfunction in the BPH patient. Eur. Urol. 2003;2(Suppl):3-8.
  10. Bouwman I., Van Der Heide W.K. et al. Correlations between lower urinary tract symptoms, erectile dysfunction, and cardiovascular diseases: Are there differences between male populations from primary healthcare and urology clinics? Eur J General. Pract. 2009; 15(3): 128-135.
  11. Mondul A.M., Rimm E.B., Giovannucci E. et al. A Prospective Study of Lower Urinary Tract Symptoms and Erectile Dysfunction. J. Urol. 2008;179(6):2321-2326.
  12. Calais Da Silva F., Marquis P., Deschaseaux P. et al. Relative impotance of sexuality and quality of life in patients with prostatic symptoms. Eur. Urol. 1997;31(3):271-280.
  13. Dean J., Hackett G.I., Gentile V. et al. Psychosocial outcomes and drug attributes affecting treatment choice in men receiving sildenafil citrate and tadalafil for the treatment of erectile dysfunction: results of a multicenter, randomized, open-label, crossover study. J. Sex. Med. 2006;3:650-661.
  14. Forgue S. T., Patterson B.E, BeddingA. W. etal.Tadalafil pharmacokinetics in healthy subjects. Br. J. Clin. Pharmacol. 2006;61:280-288.
  15. Roehrborn C., Broderick G., Brock G. et al. Once daily tadalafil improved symptoms of benign prostatic hyperplasia in men with or without history of erectile dysfunction. Eur Urol. Supplements 24th Annual EAU Congress Stockholm 17-21 March 2009.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies